BioCentury
ARTICLE | Clinical News

Updated entinostat combo data sinks Syndax shares

May 17, 2018 10:33 PM UTC

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) was off $2.51 (23%) to $8.61 on Thursday after reporting updated response data from the Phase Ib/II ENCORE 601 (KEYNOTE 142) trial of entinostat (SNDX-275) plus PD-1 inhibitor Keytruda pembrolizumab to treat melanoma, non-small cell lung cancer (NSCLC) and microsatellite stable colorectal cancer. The data were released late Wednesday in three abstracts ahead of the American Society of Clinical Oncology meeting in Chicago. Syndax reported additional updates in a press release on Thursday.

In a cohort of 34 evaluable melanoma patients who progressed on or after treatment with a PD-1/PD-L1 inhibitor, entinostat plus Keytruda led to an objective response rate (ORR) of 18%, including six confirmed partial responses (PRs). Median duration of response was 9.1 months...